A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07425899
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.

Key Dates

Start date
Feb 26, 2026
Status verified
Apr 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
32 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Period 1: Group 1
    Participants will receive multiple doses of Upadacitinib
  • Experimental: Period 1: Group 2
    Participants will receive multiple doses of Upadacitinib
  • Experimental: Period 2: Group 1
    Participants will receive multiple doses of ABBV-722
  • Experimental: Period 2: Group 2
    Participants will receive multiple doses of ABBV-722
  • Experimental: Period 3: Group 1
    Participants will receive multiple doses of ABBV-722 and Upadacitinib
  • Experimental: Period 3: Group 2
    Participants will receive multiple doses of ABBV-722 and Upadacitinib

Primary Outcome Measure

Maximum observed plasma concentration at steady state (Cmax,ss) of ABBV-722 [ Time Frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 279285GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies